Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission
NCT ID: NCT04298619
Last Updated: 2020-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
123 participants
OBSERVATIONAL
2001-06-30
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
NCT00188149
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
NCT00355199
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521
Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs
NCT05284396
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
NCT00879528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard cohort
Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
* symptom assessment
* blood tests
* physical examination
Standard cohort: Clinical lab follow-up
Imaging cohort
Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
* symptom assessment
* blood tests
* physical examination
* Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes
Standard cohort: Clinical lab follow-up
Imaging cohort: integrated imaging follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard cohort: Clinical lab follow-up
Imaging cohort: integrated imaging follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* achievement of complete response to first line therapy
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marco Picardi
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEM-FEDII-HL follow-up -001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.